Novartis secures approval from FDA for Itvisma to treat SMA

SMA is a rare genetic neuromuscular disorder and is caused by a defective or missing SMN1 gene. Credit: Panchenko Vladimir/Shutterstock.com.



  • Novartis FDA approval